Future Forward View For Biotech Companies

How biotech companies adapted to keep clinical trials moving forward during the COVID-19 pandemic
The pandemic has forced the biotech industry to quickly adapt and, as a result, is fueling the modernization of clinical trials. Agile biotech companies continue to innovate and develop new medicines, while embracing innovative new processes for decentralized trials, remote monitoring, patient enrollment, and more.
Which innovations will persist in the new normal? IQVIA facilitated a roundtable of small biotech companies to learn how they adapted during the pandemic. This article will review the biotech perspective of modern clinical trials and explore what the next normal may look like.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.